On the stock market since 2012, it operates in the world of health and science. It has 293 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 18% a year on average.
Sales run at $48.3M a year. A small number, but proof the product has real buyers.
A loss of $12.4M against $48.3M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, OPSSF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: OPSSF is a high-risk stock — not yet profitable, and its future rides on its product catching on.